Imfinzi significantly improved overall survival and progression-free survival in ADRIATIC Phase III trial
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
The approval marks a significant milestone for the American pharmaceutical company in the field of UC
The company plans to add 1700 beds by FY27 through the organic route
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Subscribe To Our Newsletter & Stay Updated